Physician profile
Brian M Patterson
NPI 1982792131
$4,507.95
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,344 · 2020: $1,017 · 2021: $146.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $793.87 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $566.27 | 2019-2021 | |
| Novo Nordisk INC | $491.95 | 2019 | |
| Pfizer INC. | $451.69 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.33 | 2019-2021 | |
| Lilly USA, LLC | $346.47 | 2019-2021 | |
| Amgen INC. | $327.52 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $264.29 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $177.54 | 2019-2020 | |
| Comsort, INC | $150.00 | 2019 | |
| Supernus Pharmaceuticals, INC. | $125.04 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $76.04 | 2019-2020 | |
| Horizon Therapeutics Plc | $36.86 | 2019-2020 | |
| Astellas Pharma US INC | $35.13 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $33.86 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $33.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.96 | 2019 | |
| Bioventus LLC | $30.18 | 2019 | |
| Merck Sharp & Dohme LLC | $28.33 | 2019 | |
| Abbott Laboratories | $24.42 | 2019 | |
| Daiichi Sankyo INC. | $24.32 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.70 | 2019 | |
| Philips North America LLC | $17.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.27 | 2019 | |
| Allergan, INC. | $11.88 | 2019 | |
| Boston Scientific Corporation | $11.78 | 2019 | |
| Amarin Pharma, INC. | $11.52 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.